Gilead ($GILD) has named Mylan ($MYL) as the exclusive distributor of branded forms of its hepatitis C blockbusters Sovaldi and Harvoni in India. The deal comes 5 months after Gilead gave Mylan and other manufacturers nonexclusive rights to produce and distribute generic versions of the drugs. Those agreements are still in place. The new deal adds another piece to Gilead's hepatitis C strategy in India by paving the way for sales of its branded products. Mylan expects to begin distribution in the second quarter of 2015. Release | More from The Wall Street Journal (sub. req.)